Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
This research is a follow-up study for adults who previously received a gene therapy treatment called AAV2-hAQP1. These individuals had severe dry mouth (xerostomia) as a result of radiation treatment for certain head and neck cancers, but not those involving the parotid glands. The main aim is to carefully observe the long-term safety and how well this gene therapy continues to work. By understanding its effects over several years, doctors hope to learn more about its potential to help people with this challenging side effect of cancer treatment. Your participation helps us understand if this treatment could offer a lasting solution for dry mouth.
At a glance
What is this study about?
Imagine your mouth feeling constantly dry, making it hard to eat, speak, or even swallow. This is a common and difficult side effect called xerostomia, which can happen to people after they've had radiotherapy for certain cancers in the head and neck area. This research study is a long-term follow-up for individuals who previously took part in an earlier study looking at a special treatment for this severe dry mouth.
The treatment being studied is a type of gene therapy called AAV2-hAQP1. It's designed to help the glands in your mouth that produce saliva work better. The 'gene therapy' part means it introduces a new gene into the cells to encourage them to produce more moisture. This study focuses on people whose dry mouth is caused by past radiotherapy, but specifically excludes cases where the parotid glands (large salivary glands near your ears) were directly affected.
The main goal of this particular follow-up study is to see how safe and effective this gene therapy is over a much longer period. Researchers want to understand if the benefits last and if there are any long-term effects. The information gathered from participants will be very important in helping doctors understand if this treatment could become a real option for many more people suffering from this often distressing side effect of cancer treatment.
Key takeaways
- This is a follow-up study, not a new treatment study.
- It's for people who previously received a gene therapy for dry mouth.
- Aims to check long-term safety and how well the treatment continues to work.
- Participation lasts for several years (4-5 years).
- Your input helps future patients with severe dry mouth.
Who may be eligible?
This follow-up study is only for a very specific group of people. To be considered, you must have already taken part in a previous study related to this gene therapy, called Study MGT-AQP1-201.
Basically, if you previously received the AAV2-hAQP1 treatment as part of that earlier study, you would be eligible for this long-term follow-up. This is because the researchers want to continue monitoring the people who have already had the treatment.
However, you cannot take part if you previously decided to stop being part of Study MGT-AQP1-201. The study is open to both men and women aged 18 and over.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Did you take part in Study MGT-AQP1-201 and receive the study treatment?
- Are you 18 years old or older?
- Did you NOT withdraw from Study MGT-AQP1-201 previously?
What does participation involve?
If you decide to take part in this follow-up study, it won't involve receiving any new treatment; it's all about checking in on your health after your previous gene therapy. The total time you'll be involved varies. If you received the treatment in Study MGT-AQP1-201, your participation will last about 48 months (four years). If you received it in a different previous study (Study MGT-AQP1-202), your participation will last at least 60 months (five years).
During this time, you will have scheduled visits with the study team. These visits will likely involve checking your general health, asking questions about your dry mouth, and possibly some tests to see how the gene therapy is still working. The aim is to carefully monitor your progress and any long-term effects of the treatment you received previously.
Potential risks and benefits
Locations (8)
- Banner MD Anderson Cancer CenterVerified postcodeGilbert, United States
- Miami Cancer Institute at Baptist Health South FloridaVerified postcodeMiami, United States
- University of IowaVerified postcodeIowa City, United States
- University of MissouriVerified postcodeColumbia, United States
- Erie County Medical CenterVerified postcodeBuffalo, United States
- Atrium HealthVerified postcodeCharlotte, United States
- Alleghany General HospitalVerified postcodePittsburgh, United States
- Shirley and Jim Fielding Northeast Cancer Centre - Health Sciences NorthVerified postcodeGreater Sudbury, Canada
Common questions
What is this study about?
This study is a long-term follow-up for people who previously received a special gene therapy for severe dry mouth caused by radiation treatment for certain cancers.
Why is this study important?
It helps doctors understand how safe and effective this gene therapy treatment is over many years, which could lead to better treatments for dry mouth in the future.
Will I get new treatment in this study?
No, this study is about monitoring your health and the effects of the treatment you received in a previous study. You won't get new treatment.
How long will I be involved?
Your involvement will last about 4 or 5 years, depending on which previous study you were part of.
Can I stop participating if I want to?
Yes, you are free to withdraw from the study at any time without it affecting your usual medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.